Sunday, 20 September 2026European Markets

VERIMATRIX Stock Bearish By 20% In The Last 10 Sessions

Loading stream...

(vianews) - shares of verimatrix (cac 40: vmx.pa) slid by a staggering 20.98% in 10 sessions from €0.77 to €0.61 at 13:14 est on friday, after two consecutive sessions in a row of losses. cac 40 is sliding 0.28% to €7,005.98, following the last session's upward trend.

about verimatrix

verimatrix société anonyme provides security solutions that protect digital content, applications, and devices worldwide. the company offers security solutions for various markets, including automotive, sports, financial services, healthcare, internet of things, live sports, media and entertainment, and tv, as well as for content owners. the company was formerly known as inside secure s.a. and changed its name to verimatrix société anonyme in july 2017. verimatrix société anonyme was founded in 1995 and is based in meyreuil, france.

earnings per share

as for profitability, verimatrix has a trailing twelve months eps of €-0.021.

more news about verimatrix (vmx.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com